Background: The potential effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICI) remains unclear. We evaluated the efficacy of different chemotherapy regimens administered after ICI in advanced non-small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICI.
Methods:We retrospectively included all patients (pts) treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group), comparing them to ICI naive patients (INP group) undergoing the same chemotherapy at Bordeaux University Hospital.The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) from the first day of chemotherapy to death and overall response rate (ORR).Results: 153 pts were included, with 34/23 (CAI/INP) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 28/12 gemcitabine (G) and 6/15 pemetrexed (PE). Age and ECOG PS did not vary significantly between CAI and INP regardless of the chemotherapy regimen except for CAI treated with PB (more pts with an ECOG PS 1 (p<0.001)). Median line number was higher in CAI for all groups. There was no difference between CAI and INP in terms of TTD, OS and ORR for all groups. However, OS tended to increase in CAI treated with PB (HR¼0.65; p¼0.17,Table]. ORR were not significantly different between CAI and INP for all the chemotherapy groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.